Skip to Content

Sitagliptin use while Breastfeeding

Drugs containing Sitagliptin: Januvia, Janumet, Janumet XR, Steglujan, Juvisync

Medically reviewed on April 2, 2018.

Sitagliptin Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the clinical use of sitagliptin during breastfeeding. If sitagliptin is required by the mother, it is not a reason to discontinue breastfeeding. However, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. Saxagliptin has a shorter half-life than the other dipeptidyl-peptidase IV inhibitors and linagliptin is highly protein bound, so these might be better choices among drugs in this class for nursing mothers.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Acarbose, Glipizide, Glyburide, Insulin, Metformin, Miglitol

References

Sitagliptin Identification

Substance Name

Sitagliptin

CAS Registry Number

486460-32-6

Drug Class

Hypoglycemic Agents

Incretins

Dipeptidyl-Peptidase IV Inhibitors

DPP-4 Inhibitors

Administrative Information

LactMed Record Number

748

Disclaimer

Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide